PACLITAXEL IN POLYMERIC NANOPARTICLES: CHALLENGES AND PERSPECTIVES IN BREAST CANCER TREATMENT
DOI:
https://doi.org/10.47820/recima21.v6i11.6952Keywords:
Paclitaxel, Polymeric nanoparticles. , Breast cancerAbstract
Breast cancer is the most prevalent malignant neoplasm among women, and Paclitaxel (PTX) stands out as one of the most effective drugs for its treatment. However, its low solubility and high toxicity limit clinical use, requiring the development of safer and more targeted delivery systems. This study aims to analyze advances in the use of polymeric nanoparticles for controlled PTX release in breast cancer treatment. The research was conducted through a narrative review of the PubMed, Scopus, ScienceDirect, and Google Scholar databases, covering the period from 2010 to 2025. The reviewed studies showed that PLGA-, PEG-, and chitosan-based nanoparticles provide greater stability, improved bioavailability, and reduced systemic toxicity, while enhancing tumor targeting. Formulations such as nab-Paclitaxel have already demonstrated superior clinical efficacy and improved safety profiles. It is concluded that polymeric nanoparticles represent a promising strategy to optimize Paclitaxel therapy, contributing to more effective and less toxic treatments, although technical and regulatory challenges still need to be overcome.
Downloads
References
ABOUZEID, Heidi A. et al. Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies. Cancer Drug Resistance, v. 8, n. 1, p. 1-22, 2025. DOI:10.1016/j.ctarc.2025.100918 DOI: https://doi.org/10.1016/j.ctarc.2025.100918
ABU SAMAAN, Tala M. et al. Efeitos mecanísticos e clínicos do Paclitaxel no câncer de mama. Biomolecules, v. 9, n. 12, p. 789, 2019. DOI: 10.3390/biom9120789 DOI: https://doi.org/10.3390/biom9120789
ALQAHTANI, Fulwah Y. et al. Drug substance profiling, excipients and related methodology. Saudi Pharmaceutical Journal, v. 27, n. 1, p. 1-16, 2019. DOI:10.1016/bs.podrm.2018.11.001 DOI: https://doi.org/10.1016/bs.podrm.2018.11.001
AMALIA, S. et al. Paclitaxel: a drug successfully developed from natural sources as breast cancer therapy. Journal of Pharmacology and Therapeutics, v. 14, n. 3, p. 45-53, 2023. Disponível em: https://www.primescholars.com/articles/Paclitaxela-drug-successfully-developed-from-natural-sources-as-breast-cancer-therapy.pdf. Acesso em: 9 out. 2025.
CHOI, Yoonjeong et al. Novel insights into the role of Paclitaxel in tumor-associated macrophages enhancing PD-1 blockade in breast cancer treatment. Cell Reports Medicine, v. 5, n. 8, p. 100984, 2024. DOI:10.1136/jitc-2024-008864 DOI: https://doi.org/10.1136/jitc-2024-008864
ELOY, Joyce O. et al. Lipossomas e imunolipossomas contendo fármacos antitumorais: desenvolvimento, caracterização e avaliação da eficácia contra o câncer de mama. 2016. Tese (Doutorado em Ciências Farmacêuticas) – Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 2016. Disponível em: https://www.teses.usp.br/teses/disponiveis/60/60137/tde03102016153049/publico/Tese_CORRIGIDA_Completa.pdf. Acesso em: 9 out. 2025.
GALLEGO-JARA, Júlia et al. A comprehensive review on Taxol®: history and future challenges. Molecules, v. 25, n. 24, p. 5986, 2020. DOI:10.3390/molecules25245986 DOI: https://doi.org/10.3390/molecules25245986
MANSO, Vitória Abdala et al. Avaliação do uso de nanotecnologia na quimioterapia neoadjuvante para o câncer de mama: uma revisão de evidências e classificação GRADE. Brazilian Journal of Health Review, v. 7, n. 3, p. 31290-31308, 2024. DOI:10.34119/bjhrv7n9-046 DOI: https://doi.org/10.34119/bjhrv7n9-046
ROSKOSKI JR, Robert et al. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacology & Therapeutics, v. 256, p. 108617, 2024. DOI: 10.1016/j.phrs.2024.107534 DOI: https://doi.org/10.1016/j.phrs.2024.107534
WANG, Feihu et al. Pre-clinical development of drug delivery systems for cancer chemotherapy based on Paclitaxel. Acta Pharmaceutica Sinica B, v. 7, n. 5, p. 439-458, 2017. DOI: 10.1016/j.jconrel.2017.09.026 DOI: https://doi.org/10.1016/j.jconrel.2017.09.026
Downloads
Published
License
Copyright (c) 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
